San Diego-primarily based Viking Therapeutics marked alone as a serious competitor in the weight loss drug industry in February immediately after revealing promising data from a mid-phase demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when supplied for a weekly injection and in March the com